Oct. 7, 2009 (Business Wire) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that three abstracts have been accepted for presentation at the American Society of Nephrology (ASN) Renal Week meeting being held October 27-November 1, 2009 in San Diego, CA. Full abstracts can now be viewed on the ASN website at www.asn-online.org.
The three accepted abstracts are as follows:
- “Hemoglobin Response by Baseline Hemoglobin and Iron Indices Following IV Ferumoxytol Treatment in Nondialysis CKD Patients” (Bolton et al.) – Abstract # 1088: Poster presentation;
10 am-12 pm, Friday, October 30, 2009 - “Gastrointestinal Tolerability of IV Ferumoxytol and Oral Iron Therapy in Patients with Iron Deficiency Anemia and Chronic Kidney Disease” (Spinowitz et al.) – Abstract #1093: Poster presentation; 10 am-12 pm, Friday, October 30, 2009
- “MRI-Based Renal Imaging with Ferumoxytol: Perfusion-Enhanced MRI in a Rabbit Model” (Lewis et al.) – Abstract #2979: Poster presentation; 10 am-12 pm, Saturday, October 31, 2009
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG recently received approval from the U.S. Food and Drug Administration to market Feraheme™ (ferumoxytol) Injection for intravenous use for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit www.amagpharma.com.
Feraheme™ is a trademark of AMAG Pharmaceuticals, Inc.
